ATA-200

Phase 1Biologic

AAtamyo Therapeutics

ATA-200 is one of 4 biologic programs targeting Gene Therapy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gene TherapyActive, not recruiting

Gene TherapyPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Gene Therapy

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Phase 2

2 2

BMN 333

BioMarin Pharmaceutical

Phase 2

1 3

ATA-200

AAtamyo Therapeutics

Phase 1

1 4

Raav2-ND4

BBin Li

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Active, not recruiting

Gene Therapy

NCT05973630

Clinical

Trials by Indication[1]

Gene Therapy1 trial

ATA-200 Gene Therapy Trial in Patients With LGMDR5

Active, not recruiting·AAtamyo Therapeutics·Phase 1·NCT05973630·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATA-200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATA-200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATA-200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atamyo Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAtamyo Therapeutics

ATA-200

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Gene Therapy1 trial

References

Drug Info

Quick Facts

Related News